Mylan has previously fought against its competitor Teva Pharmaceutical Industries' application to the FDA for approval of its generic EpiPen
You have no items in your shopping cart.
You have no items in your shopping cart.
Mylan has previously fought against its competitor Teva Pharmaceutical Industries' application to the FDA for approval of its generic EpiPen
Mylan’s CEO Heather Bresch, who saw her compensation increase by nearly 700% from 2007 to 2015, could draw "greater regulatory scrutiny and headline risk" as a result of such price increases.
The Cambridge-based startup is aimed at furthering technologies in "immuno-oncology" – drugs that tackle the immune system to better attack cancer cells.